

B. Appendix B- Measure Name Crosswalk

Hospital IQR Program Measure Name Crosswalk

Acute Myocardial Infarction

NQF #	Hospital Compare Measure Name	NQF Measure Name
0132	Heart Attack Patients Given Aspirin at Arrival	Aspirin at Arrival for Acute Myocardial Infarction (AMI)
0142	Heart Attack Patients Given Aspirin at Discharge	Aspirin Prescribed at Discharge for AMI
0137	Heart Attack Patients Given ACE Inhibitor or ARB for Left Ventricular Systolic Dysfunction (LVSD)	ACEI or ARB for Left Ventricular Systolic Dysfunction- Acute Myocardial Infarction (AMI) Patients
157	Heart Attack Patients Given Smoking Cessation Advice/Counseling	Smoking Cessation Counseling for Acute Myocardial Infarction
0160	Heart Attack Patients Given Beta Blocker at Discharge	Beta Blocker Prescribed at Discharge for AMI
153	Heart Attack Patients Given Beta Blocker at Arrival	Beta Blocker at Arrival for Acute Myocardial Infarction (AMI)
0164	Heart Attack Patients Given Fibrinolytic Medication Within 30 Minutes Of Arrival	Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival
0163	Heart Attack Patients Given PCI Within 90 Minutes Of Arrival	Primary PCI Within 90 Minutes of Hospital Arrival
0505	(Risk-Adjusted) Rate of Readmission for Heart Attack Patients	Thirty-Day All-Cause Risk Standardized Readmission Rate Following Acute Myocardial Infarction (AMI) Hospitalization
0230	(Risk-Adjusted) Death Rate for Heart Attack Patients	Acute Myocardial Infarction 30-day Mortality

Heart Failure

NQF #	Hospital Compare Measure Name	NQF Measure Name
0136	Heart Failure Patients Given Discharge Instructions	Heart Failure (HF): Detailed Discharge Instructions
0135	Heart Failure Patients Given an Evaluation of Left Ventricular Systolic (LVS) Function	Evaluation of Left ventricular Systolic Function (LVS)
0162	Heart Failure Patients Given ACE Inhibitor or ARB for Left Ventricular Systolic Dysfunction (LVSD))	Heart Failure: Angiotensin Converting Enzyme Inhibitor (ACEI) for Left Ventricular Systolic Dysfunction (LVSD)
158	Heart Failure Patients Given Smoking Cessation Advice/Counseling	Adult Smoking Cessation Advice/Counseling for HF
0330	(Risk Adjusted) Rate of Readmission for Heart Failure Patients	30-Day All-Cause Risk Standardized Readmission Rate Following Heart Failure Hospitalization (risk adjusted)
0229	(Risk Adjusted) Death Rate for Heart Failure Patients	Heart Failure 30-day Mortality

Pneumonia

NQF #	Hospital Compare Measure Name	NQF Measure Name
146	Oxygenation Assessment	Oxygenation Assessment
0150	Pneumonia Patients Assessed and Given Pneumococcal Vaccination	Pneumococcal Vaccination
0148	Pneumonia Patients Whose Initial Emergency Room Blood Culture Was Performed Prior to the Administration Of The First Hospital Dose Of Antibiotics	Blood Cultures Performed in the Emergency Department Prior to Initial Antibiotic Received in Hospital
159	Pneumonia Patients Given Smoking Cessation Advice/Counseling	Smoking Cessation Counseling for Pneumonia
0151	Pneumonia Patients Given Initial Antibiotic(s) Within 6 Hours After Arrival	Initial Antibiotic Received Within 6 Hours of Hospital Arrival
0147	Pneumonia Patients Given the Most Appropriate Initial Antibiotic(s)	Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients
0149	Pneumonia Patients Assessed and Given Influenza Vaccination	Influenza Vaccination
0506	(Risk-Adjusted) Rate of Readmission for Pneumonia Patients	Thirty-Day All-Cause Risk Standardized Readmission Rate Following Pneumonia Hospitalization.
0468	(Risk-Adjusted) Death Rate for Pneumonia Patients	Pneumonia (PN) 30-Day Mortality Rate

Surgical Care Improvement Project

NQF #	Hospital Compare Measure Name	NQF Measure Name
0284	Surgery Patients Who Were Taking Heart Drugs Called Beta Blockers Before Coming to the Hospital, Who Were Kept on the Beta Blockers During the Period Just Before and After Their Surgery	Surgery Patients on Beta Blocker Therapy Prior to Admission Who Received a Beta Blocker During the Perioperative Period
0527	Surgery Patients Who Were Given an Antibiotic at the Right Time (Within One Hour Before Surgery) to Help Prevent Infection	Prophylactic Antibiotic Received Within 1 Hour Prior to Surgical Incision
0528	Surgery Patients Who Were Given the Right Kind of Antibiotic to Help Prevent Infection	Prophylactic Antibiotic Selection for Surgical Patients
0529	Surgery Patients Whose Preventive Antibiotics Were Stopped at the Right Time (Within 24 Hours After Surgery)	Prophylactic Antibiotics Discontinued Within 24 Hours After Surgery End Time
0300	Heart Surgery Patients Whose Blood Sugar (Blood Glucose) Is Kept Under Good Control in the Days Right After Surgery	Cardiac Patients With Controlled 6AM Postoperative Serum Glucose
0301	Surgery Patients Needing Hair Removed From the Surgical Area Before Surgery, Who Had Hair Removed Using a Safer Method (Electric Clippers or Hair Removal Cream – Not a Razor)	Surgery Patients With Appropriate Hair Removal

NQF #	Hospital Compare Measure Name	NQF Measure Name
0217	Surgery Patients Whose Doctors Ordered Treatments to Prevent Blood Clots After Certain Types of Surgeries	Surgery Patients With Recommended Venous Thromboembolism (VTE) Prophylaxis Ordered
0218	Patients Who Got Treatment at the Right Time (Within 24 Hours Before or After Their Surgery) to Help Prevent Blood Clots After Certain Types of Surgery	Surgery Patients Who Received Appropriate Venous Thromboembolism (VTE) Prophylaxis Within 24 Hours Prior to Surgery to 24 Hours After Surgery End Time

Hospital Consumer Assessment of Healthcare Providers and Systems

NQF #	Hospital Compare Measure Name	NQF Measure Name
0166	HCAHPS	27-items Survey Instrument with 7 Domain-Level Composites.
	Communication with Nurses	Communication With Nurses
	Communication with Doctors	Communication With Doctors
	Responsiveness of Hospital Staff	Responsiveness of Staff
	Pain Control	Pain Management
	Communication About Medicines	Communication about Medicines
	Cleanliness of the Hospital Environment	Cleanliness of Hospital
	Quietness of the Hospital Environment	Quietness of Hospital
	Discharge Information	Discharge Information
	Hospital Rating	Overall Hospital Rating
	Recommend Hospital	Recommend the Hospital

Hospital Outpatient Quality Reporting Program Measure Name Crosswalk

Heart Attack or Chest Pain Process-of-Care Measures

NQF #	Hospital Compare Measure Name	NQF Measure Name
0287	Median Time to Fibrinolysis (Not Currently Reported on Hospital Compare)	Median Time to Fibrinolysis
0288	Outpatients with Chest Pain or Possible Heart Attack Who Got Drugs to Break Up Blood Clots within 30 Minutes of Arrival	Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival

NQF #	Hospital Compare Measure Name	NQF Measure Name
0290	Average Number of Minutes Before Outpatients with Chest Pain or Possible Heart Attack Who Needed Specialized Care Were Transferred to Another Hospital	Median Time to Transfer to Another Facility for Acute Coronary Intervention
0286	Outpatients with Chest Pain or Possible Heart Attack Who Got Aspirin within 24 Hours of Arrival	Aspirin at Arrival
0289	Average Number of Minutes Before Outpatients with Chest Pain or Possible Heart Attack Got an ECG	Median to ECG

Surgical Care

NQF #	Hospital Compare Measure Name	NQF Measure Name
0270	Outpatients Having Surgery Who Got an Antibiotic at the Right Time - Within One Hour Before Surgery	Timing of Antibiotic Prophylaxis: Ordering Physician.
0268	Outpatients Having Surgery Who Got the Right Kind of Antibiotic	Selection of Prophylactic Antibiotic: First OR Second

Outpatient Imaging Efficiency

NQF #	Hospital Compare Measure Name	NQF Measure Name
0513	Outpatient CT Scans of the Chest That Were "Combination" (Double) Scans	Use of Contrast: Thorax CT
0514	Outpatients With Low Back Pain Who Had an MRI Without Trying Recommended Treatments First, Such as Physical Therapy	MRI Lumbar Spine for Low Back Pain

Physician Quality Reporting System Measure Name Crosswalk

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
0059	1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	Hemoglobin A1c Management	Percentage of adult patients with diabetes aged 18–75 years with most recent A1c level greater than 9.0% (poor control)
0064	2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	Diabetes Measure Pair: A Lipid Management: Low Density Lipoprotein Cholesterol (LDL-C) < 130, B Lipid Management: LDL-C < 100	Percentage of adult patients with diabetes aged 18–75 years with most recent (LDL-C) < 130 mg/dL B: Percentage of patients 18–75 years of age with diabetes whose most recent LDL-C test result during the measurement year was < 100 mg/dL
0061	3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	Diabetes: Blood Pressure Management	Percentage of patient visits with blood pressure measurement recorded among all patient visits for patients aged > 18 years with

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
				diagnosed hypertension
0081	5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	Heart Failure (HF) : ACEI/ ARB Therapy	Percentage of patients with HF who also have left ventricular systolic dysfunction (LVSD) who were prescribed ACE inhibitor or ARB therapy
0067	6	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	CAD: Antiplatelet Therapy	Percentage of patients with CAD who were prescribed antiplatelet therapy
0070	7	Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)	CAD: Beta-Blocker Therapy-Prior Myocardial Infarction (MI)	Percentage of patients with prior MI at any time who were prescribed beta-blocker therapy
0083	8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	Heart Failure (HF) : Beta-Blocker Therapy	Percentage of patients with HF who also have LVSD who were prescribed beta-blocker therapy
0105	9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	New Episode of Depression: Effective Acute Phase Treatment	Percentage of patients who were diagnosed with a new episode of depression, were treated with antidepressant medication and remained on an antidepressant drug during the entire 84-day Acute Treatment Phase
0246	10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	Percentage of final reports for CT or MRI studies of the brain performed within 24 hours of arrival to the hospital for patients aged 18 years and older with the diagnosis of ischemic stroke or TIA or intracranial hemorrhage that includes documentation of the presence or absence of each of the following: hemorrhage and mass lesion and acute infarction
0086	12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	Primary Open Angle Glaucoma: Optic Nerve Evaluation	Percentage of patients aged 18 years and older with a diagnosis of primary open-angle glaucoma (POAG) who have an optic nerve head evaluation during one or more office visits within 12 months
0087	14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	Age-Related Macular Degeneration: Dilated Macular Examination	Percentage of patients aged 50 years and older with a diagnosis of age-related macular degeneration that had a dilated

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
				macular examination performed which included documentation of the presence or absence of macular thickening or hemorrhage AND the level of macular degeneration severity during one or more office visits within 12 months
0088	18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy AND the presence or absence of macular edema during one or more office visits within 12 months
0089	19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes regarding the findings of the macular or fundus exam at least once within 12 months
0270	20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	Perioperative Care: Timing of Antibiotic Prophylaxis: Ordering Physician	Percentage of surgical patients aged 18 years and older undergoing procedures with the indications for prophylactic parenteral antibiotics, who have an order for prophylactic antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours), prior to the surgical incision (or start of procedure when no incision is required)
0268	21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	Perioperative Care: Selection of Prophylactic Antibiotic: First OR Second Generation Cephalosporin	Percentage of surgical patients aged 18 years and older undergoing procedures with the indications for a first OR second generation cephalosporin prophylactic antibiotic, who had an order for cefazolin OR cefuroxime for antimicrobial

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
				prophylaxis
0271	22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	Percentage of non-cardiac surgical patients aged 18 years and older undergoing procedures with the indications for prophylactic antibiotics AND who received a prophylactic antibiotic, who have an order for discontinuation of prophylactic antibiotics within 24 hours of surgical end time
0239	23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis	Percentage of patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients, who had an order for Low Molecular Weight Heparin (LMWH), Low-Dose Unfractionated Heparin (LDUH), adjusted-dose warfarin, fondaparinux or mechanical prophylaxis to be given within 24 hours prior to incision time or within 24 hours after surgery end time
0045	24	Osteoporosis: Communication with the Physician Managing Ongoing Care Post-Fracture of Hip, Spine, or Distal Radius for Men and Women Aged 50 Years and Older	Osteoporosis: Communication with the Physician Managing Ongoing Care Post-Fracture	Percentage of patients aged 50 years and older treated for a hip, spine, or distal radial fracture with documentation of communication with the physician managing the patient's ongoing care that a fracture occurred and that the patient was or should be tested or treated for osteoporosis
0092	28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	Aspirin at Arrival of AMI	Percentage of patients with an emergency department discharge diagnosis of AMI who had documentation of receiving aspirin within 24 hours before emergency department arrival or during emergency department stay
0269	30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	Perioperative Care: Timing of Prophylactic Antibiotics—Administering Physician	Percentage of surgical patients aged > 18 years with indications for prophylactic parenteral antibiotics for whom administration of the antibiotic

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
				has been initiated within one hour (if vancomycin, two hours) prior to the surgical incision or start of procedure when no incision is required
0240	31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage	Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	Percentage of patients aged 18 years and older with the diagnosis of ischemic stroke or intracranial hemorrhage who received Deep Vein Thrombosis (DVT) prophylaxis by the end of hospital day two (2)
0325	32	Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy	Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy	Percentage of patients aged 18 years and older with the diagnosis of ischemic stroke or transient ischemic attack (TIA) who were prescribed antiplatelet therapy at discharge
0241	33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge	Percentage of patients aged 18 years and older with the diagnosis of ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal atrial fibrillation who were prescribed an anticoagulant at discharge
0243	35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	Stroke and Stroke Rehabilitation: Screening for Dysphagia	Percentage of patients aged 18 years and older with the diagnosis of ischemic stroke or intracranial hemorrhage who receive any food, fluids, or medication by mouth who underwent a dysphagia screening process before taking any foods, fluids, or medication by mouth
0244	36	Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services	Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services	Percentage of patients aged 18 years and older with the diagnosis of ischemic stroke or intracranial hemorrhage for whom consideration of rehabilitation services (ordered rehabilitation or documented that rehabilitation was not indicated) is documented
0046	39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	Osteoporosis: Screening or Therapy for Women Aged 65 Years and Older	Percentage of female patients aged 65 years and older who have a central DXA measurement ordered or

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
				performed at least once since age 60 or pharmacologic therapy prescribed within 12 months
0048	40	Osteoporosis: Management Following Fracture of Hip, Spine, or Distal Radius for Men and Women Aged 50 Years and Older	Osteoporosis: Management Following Fracture	Percentage of patients aged 50 years or older with fracture of the hip, spine, or distal radius that had a central DXA measurement ordered or performed or pharmacologic therapy prescribed
0049	41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	Osteoporosis: Pharmacologic Therapy	Percentage of patients aged 50 years and older with a diagnosis of osteoporosis who were prescribed pharmacologic therapy within 12 months
0134	43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	Coronary artery bypass graft (CABG) using internal mammary artery (IMA)	Percentage of coronary artery bypass graft (CABG) using internal mammary artery (IMA)
0236	44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	Pre-op Beta Blocker in Patient with Isolated CABG (2)	Percentage of patients undergoing CABG with documented pre-operative beta blockade who had a coronary artery bypass graft
0637	45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	Percentage of cardiac surgical patients aged 18 years and older undergoing procedures with the indications for prophylactic antibiotics AND who received a prophylactic antibiotic, who have an order for discontinuation of prophylactic antibiotics within 48 hours of surgical end time
0097	46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	Medication Reconciliation: After Discharge from an Inpatient Facility	Percentage of patients aged 65 years and older discharged from any inpatient facility (e.g., hospital, skilled nursing facility, or rehabilitation facility) and seen within 60 days following discharge in the office by the physician providing ongoing care who had a reconciliation of the discharge medications with the current medication list in the medical record documented

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
0326	47	Advance Care Plan	Advance Care Plan	Percentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan
0098	48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women	Percentage of female patients aged 65 years and older who were assessed for the presence or absence of urinary incontinence within 12 months
0099	49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	Urinary Incontinence: Characterization of Urinary Incontinence in Women	Percentage of female patients aged 65 years and older with a diagnosis of urinary incontinence whose urinary incontinence was characterized at least once within 12 months
0100	50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women	Percentage of female patients aged 65 years and older with a diagnosis of urinary incontinence with a documented plan of care for urinary incontinence at least once within 12 months
0091	51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	COPD: Spirometry Evaluation	Percentage of patients with COPD who had a spirometry evaluation documented
0102	52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	COPD: Inhaled Bronchodilator Therapy	Percentage of symptomatic patients with COPD who were prescribed an inhaled bronchodilator
0047	53	Asthma: Pharmacologic Therapy	Asthma: Pharmacologic Therapy	Percentage of all patients with mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment
0090	54	12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	Electrocardiogram Performed for Non-Traumatic Chest Pain	Percentage of patients aged 40 years and older with an emergency department discharge diagnosis of non-

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
				traumatic chest pain who had an electrocardiogram (ECG) performed
0093	55	12-Lead Electrocardiogram (ECG) Performed for Syncope	Electrocardiogram Performed for Syncope	Percentage of patients aged 18 years and older with an emergency department discharge diagnosis of syncope who had an ECG performed
0232	56	Community-Acquired Pneumonia (CAP): Vital Signs	Vital Signs for Community-Acquired Bacterial Pneumonia	Percentage of patients aged 18 years and older with a diagnosis of community-acquired bacterial pneumonia with vital signs (temperature, pulse, respiratory rate, and blood pressure) documented and reviewed
0094	57	Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia	Percentage of patients aged 18 years and older with the diagnosis of community-acquired bacterial pneumonia with oxygen saturation assessed
0095	58	Community-Acquired Pneumonia (CAP): Assessment of Mental Status	Assessment Mental Status for Community-Acquired Bacterial Pneumonia	Percentage of patients aged 18 years and older with the diagnosis of community-acquired bacterial pneumonia with mental status assessed
0096	59	Community-Acquired Pneumonia (CAP): Empiric Antibiotic	Empiric Antibiotic for Community-Acquired Bacterial Pneumonia	Percentage of patients aged 18 years and older with the diagnosis of community-acquired bacterial pneumonia with an appropriate empiric antibiotic prescribed
0001	64	Asthma: Asthma Assessment	Asthma Assessment	Percentage of patients who were evaluated during at least one office visit for the frequency (numeric) of daytime and nocturnal asthma symptoms
0069	65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	Percentage of children who were given a diagnosis of URI and were not dispensed an antibiotic prescription on or three days after the episode date
0002	66	Appropriate Testing for Children with Pharyngitis	Appropriate Testing for Children with Pharyngitis	Percentage of patients who were diagnosed with pharyngitis, prescribed an antibiotic, and who received a group A streptococcus test for the episode

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
0377	67	Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	Myelodysplastic Syndrome (MDS) and Acute Leukemias Baseline Cytogenetic Testing Performed on Bone Marrow	Percentage of patients aged 18 years and older with a diagnosis of MDS or an acute leukemia who had baseline cytogenetic testing performed on bone marrow
0378	68	Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	Percentage of patients aged 18 years and older with a diagnosis of MDS who are receiving erythropoietin therapy with documentation of iron stores prior to initiating erythropoietin therapy
0380	69	Multiple Myeloma: Treatment with Bisphosphonates	Multiple Myeloma Treatment with Bisphosphonates	Percentage of patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission, who were prescribed or received intravenous bisphosphonates within the 12 month reporting period
0379	70	Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	Chronic Lymphocytic Leukemia (CLL) Baseline Flow Cytometry	Percentage of patients aged 18 years and older with a diagnosis of CLL who had baseline flow cytometry studies performed
0387	71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	Oncology: Hormonal Therapy for Stage IC Through IIIC, ER/PR Positive Breast Cancer	Percentage of female patients aged 18 years and older with Stage IC through IIIC, estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) within the 12-month reporting period
0385	72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	Oncology: Chemotherapy for Stage IIIA Through IIIC Colon Cancer Patients	Percentage of patients aged 18 years and older with Stage IIIA through IIIC colon cancer who are prescribed or who have received adjuvant chemotherapy within the 12-month reporting period
0464	76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	Anesthesiology and Critical Care: Prevention of Catheter-Related Bloodstream Infections (CRBSI) Central Venous Catheter (CVC) Insertion Protocol	Percentage of patients who undergo CVC insertion for whom CVC was inserted with all elements of maximal sterile barrier technique (cap AND mask AND sterile gown AND sterile gloves AND a large sterile sheet AND hand hygiene AND 2% chlorhexidine for cutaneous

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
				antiseptics) followed
0227	79	End-Stage Renal Disease (ESRD): Influenza Immunization in Patients with ESRD	End-Stage Renal Disease (ESRD): Influenza Immunization	Percentage of patients aged 18 years and older with a diagnosis of ESRD and receiving dialysis who received the influenza immunization during the flu season (September through February)
0323	81	End-Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients	End-Stage Renal Disease (ESRD): Hemodialysis Adequacy/Plan of Care	Percentage of calendar months within a 12-month period during which patients aged 18 years and older with a diagnosis of ESRD receiving hemodialysis three times a week have a spKt/V ≥ 1.2
0321	82	End-Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis	End-Stage Renal Disease (ESRD): Peritoneal Dialysis Adequacy/Plan of Care	Percentage of calendar months within a 12-month period during which patients aged 18 years and older with a diagnosis of ESRD receiving hemodialysis three times a week have a spKt/V ≥ 1.2
0393	83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia	Hepatitis C: Testing for Chronic Hepatitis C - Confirmation of Hepatitis C Viremia	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C seen for an initial evaluation who had HCV RNA testing ordered or previously performed
0395	84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	Paired Measure: Hepatitis C RNA Testing Before Initiating Treatment (paired with 0396)	Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed within 6 months prior to initiation of antiviral treatment
0396	85	Hepatitis C: HCV Genotype Testing Prior to Treatment	Paired Measure: HCV Genotype Testing Prior to Treatment (paired with 0395)	Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom HCV genotype testing was performed within 6 months prior to initiation of antiviral treatment
0397	86	Hepatitis C: Antiviral Treatment Prescribed	Hepatitis C: Prescribed Antiviral Therapy	Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who were prescribed peginterferon and

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
				ribavirin therapy within the 12-month reporting period
0398	87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	Hepatitis C: HCV RNA Testing at Week 12 of Treatment	Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed at 12-weeks from initiation of antiviral treatment
0401	89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who received counseling regarding the risk of alcohol consumption at least once within the 12 month reporting period
0394	90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Treatment	Percentage of female patients aged 18 to 44 years and all men aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment who were counseled regarding contraception prior to the initiation of antiviral treatment
0653	91	Acute Otitis Externa (AOE): Topical Therapy	Acute Otitis Externa: Topical Therapy	Percentage of patients aged 2 years and older with a diagnosis of AOE who were prescribed topical preparations
0654	93	Acute Otitis Externa (AOE): Pain Assessment	Acute Otitis Externa: Systemic Antimicrobial Therapy Avoidance of Inappropriate Use	Percentage of patients aged 2 years and older with a diagnosis of AOE who were not prescribed systemic antimicrobial therapy
0391	99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	Breast Cancer Resection Pathology Reporting—pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	Percentage of breast cancer resection pathology reports that include the pT category (primary tumor), the pN category (regional lymph nodes), and the histologic grade
0392	100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	Colorectal Cancer Resection Pathology Reporting—pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	Percentage of colon and rectum cancer resection pathology reports that include the pT category (primary tumor), the pN category (regional lymph nodes), and the histologic grade
0389	102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate	Prostate Cancer: Avoidance of Overuse Measure Isotope Bone Scan for Staging Low-Risk	Percentage of patients with a diagnosis of prostate cancer, at low risk of recurrence, receiving

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
		Cancer Patients	Patients	interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer
0390	104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Patients	Percentage of patients with a diagnosis of prostate cancer, at high risk of recurrence, receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist)
0388	105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy	Prostate Cancer: Three-Dimensional Radiotherapy	Percentage of patients with prostate cancer receiving external beam radiotherapy to the prostate only who receive 3D-CRT (three-dimensional conformal radiotherapy) or IMRT (intensity modulated radiation therapy)
0103	106	Major Depressive Disorder (MDD): Diagnostic Evaluation	Major Depressive Disorder: Diagnostic Evaluation	Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of MDD who met the DSM-IV criteria during the visit in which the new diagnosis or recurrent episode was identified during the measurement period
0104	107	Major Depressive Disorder (MDD): Suicide Risk Assessment	Major Depressive Disorder: Suicide Risk Assessment	Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of major depressive disorder (MDD) who had a suicide risk assessment completed at each visit during the measurement period
0054	108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	Arthritis: Disease Modifying Antirheumatic Drug (DMARD) Therapy in Rheumatoid Arthritis	Percentage of patients 18 years and older, diagnosed with rheumatoid arthritis who have had at least one ambulatory prescription dispensed for a DMARD
0050	109	Osteoarthritis (OA): Function and Pain Assessment	Osteoarthritis: Function and Pain Assessment	Percentage of patients with osteoarthritis who were assessed for function and pain

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
0041	110	Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old	Influenza Vaccination: Influenza Immunization for Patients ≥ 50 Years Old	Percentage of patients who received an influenza vaccination
0043	111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	Pneumonia Vaccination Status for Older Adults	Percentage of patients 65 years of age and older who ever received a pneumococcal vaccination
0031	112	Preventive Care and Screening: Screening Mammography	Breast Cancer Screening	Percentage of eligible women 40–69 who receive a mammogram in a two-year period
0034	113	Preventive Care and Screening: Colorectal Cancer Screening	Colorectal Cancer Screening	Percentage of adults 50–80 years of age who had appropriate screening for colorectal cancer (CRC) including fecal occult blood test during the measurement year or, flexible sigmoidoscopy during the measurement year or the four years prior to the measurement year or, double contrast barium enema during the measurement year or the four years prior to the measurement year or, colonoscopy during the measurement year or the nine years prior to the measurement year
0028	114	Preventive Care and Screening: Inquiry Regarding Tobacco Use	Tobacco Use Assessment	Percentage of patients who were queried about tobacco use one or more times during the two-year measurement period
0027	115	Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit	Smoking Cessation: Advising Smokers to Quit	Percentage of patients who received advice to quit smoking
0058	116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	Inappropriate antibiotic treatment for adults with acute bronchitis	Percentage of patients who were diagnosed with bronchitis and were dispensed an antibiotic on or within three days after the episode date
0055	117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	Diabetes: Eye exam	Percentage of adult patients with diabetes aged 18-75 years who received a dilated eye exam or seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
				or imaging validated to match diagnosis from these photos during the reporting year, or during the prior year, if patient is at low risk** for retinopathy <i>**Patient is considered low risk if the following criterion is met: has no evidence of retinopathy in the prior year</i>
0066	118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) a	CAD: ACE Inhibitor/Angiotensin Receptor Blocker (ARB) Therapy	Percentage of patients with CAD who also have diabetes and/or LVSD who were prescribed ACE inhibitor or ARB therapy
0062	119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	Diabetes: Urine Protein Screening	Percentage of adult diabetes patients aged 18–75 years with at least one test for microalbumin during the measurement year or who had evidence of medical attention for existing nephropathy (diagnosis of nephropathy or documentation of microalbuminuria or albuminuria)
0488	124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	Adoption of Health Information Technology	Documents whether provider has adopted and is using health information technology. To qualify, the provider must have adopted and be using a certified/qualified electronic health record (EHR)
0417	126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	Diabetic Foot & Ankle Care, Peripheral Neuropathy Neurological Evaluation	Percentage of patients with diabetes, 18 years or older, who had a lower extremity neurological exam with risk categorization performed and a treatment plan established during one or more office visits within 12 months
0416	127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	Diabetic Foot & Ankle Care, Ulcer Prevention Evaluation of Footwear	Percentage of patients aged 18 years and older with a diagnosis of diabetes mellitus who were evaluated for proper footwear and sizing during one or more office visits within 12 months
0421	128	Preventive Care and Screening:	Adult Weight Screening and	Percentage of patients aged 18

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
		Body Mass Index (BMI) Screening and Follow-Up	Follow-Up	years and older with a calculated BMI documented in the medical record AND if the most recent BMI is outside the parameters, a follow-up plan is documented Parameters: age 65 and older BMI ≥ 30 or < 22 ; age 18–64 BMI ≥ 25 or < 18.5
0419	130	Documentation and Verification of Current Medications in the Medical Record	Universal Documentation and Verification of Current Medications in the Medical Record	Percentage of patients aged 18 years and older with a list of current medications with dosages (includes prescription, over-the-counter, herbals, vitamin/mineral/dietary [nutritional] supplements) and verified with the patient or authorized representative documented by the provider
0420	131	Pain Assessment Prior to Initiation of Patient Therapy and Follow-Up	Pain Assessment Prior to Initiation of Patient Therapy	Percentage of patients with documentation of a pain assessment (if pain is present, including location, intensity, and description) through discussion with the patient including the use of a standardized tool on each initial evaluation prior to initiation of therapy and documentation of a follow-up plan
0418	134	Screening for Clinical Depression and Follow-Up Plan	Screening for Clinical Depression	Percentage of patients aged 18 years and older screened for clinical depression using a standardized tool and follow-up plan documented
0650	137	Chronic Kidney Disease (CKD): Influenza Immunization	Melanoma Continuity of Care Recall System	Percentage of patients with a current diagnosis of melanoma or a history of melanoma who were entered into a recall system with the date for the next complete physical skin exam specified, at least once within the 12-month reporting period
0561	138	Melanoma: Follow-Up Aspects of Care	Melanoma Coordination of Care	Percentage of patients seen with a new occurrence of melanoma who have a treatment plan documented in the chart that was communicated to the

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
				physician(s) providing continuing care within one month of diagnosis
0566	140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	Percentage of patients aged 50 years and older with a diagnosis of age-related macular degeneration or their caregiver(s) who were counseled within 12 months on the benefits and/or risks of the AREDS formulation for preventing progression of AMD
0563	141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	Primary Open-Angle Glaucoma: Reduction of Intraocular Pressure by 15% or Documentation of a Plan of Care	Percentage of patients aged 18 years and older with a diagnosis of primary open-angle glaucoma whose glaucoma treatment has not failed (the most recent IOP was reduced by at least 15% from the pre-intervention level) OR if the most recent IOP was not reduced by at least 15% from the pre-intervention level a plan of care was documented within 12 months
0051	142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	Osteoarthritis: Assessment for Use of Anti-inflammatory or Analgesic Over-the-Counter (OTC) Medications	Percentage of patient visits with assessment for use of anti-inflammatory or analgesic OTC medications
0384	143	Oncology: Medical and Radiation – Pain Intensity Quantified	Oncology: Pain Intensity Quantified Medical Oncology and Radiation Oncology (paired with 0383)	Percentage of visits for patients with a diagnosis of cancer currently receiving intravenous chemotherapy or radiation therapy in which pain intensity is quantified
0383	144	Oncology: Medical and Radiation – Plan of Care for Pain	Oncology: Plan of Care for Pain Medical Oncology and Radiation Oncology (paired with 0384)	Percentage of visits for patients with a diagnosis of cancer currently receiving intravenous chemotherapy or radiation therapy who report having pain with a documented plan of care to address pain
0510	145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	Exposure Time Reported for Procedures Using Fluoroscopy	Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time
0508	146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography	Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening	Percentage of final reports for screening mammograms that are classified as “probably

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
		Screening		benign”
0511	147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	Correlation With Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., x-ray, MRI, CT) that were performed
0382	156	Oncology: Radiation Dose Limits to Normal Tissues	Oncology: Radiation Dose Limits to Normal Tissues	Percentage of patients with a diagnosis of cancer receiving 3D conformal radiation therapy with documentation in medical record that normal tissue dose constraints were established within five treatment days for a minimum of one tissue
0455	157	Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	Percentage of all surgical patients undergoing treatment procedures for lung or esophageal cancer that have clinical TNM staging provided
0466	158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	Use of Patch during Conventional Carotid Endarterectomy	Percentage of patients aged 18 years and older undergoing conventional (non-eversion) carotid endarterectomy who undergo patch closure of the arteriotomy
0404	159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	HIV/AIDS: CD4+ Cell Count	Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with a CD4+ cell count or CD4+ cell percentage performed at least once every 6 months
0405	160	HIV/AIDS: <i>Pneumocystis jiroveci</i> Pneumonia (PCP) Prophylaxis	HIV/AIDS: PCP prophylaxis	Percentage of patients aged 1 month or older who were prescribed <i>Pneumocystis jiroveci</i> pneumonia (PCP) prophylaxis
0406	161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	Adolescent and Adult Clients with AIDS Who Are Prescribed Potent ART (PROCESS MEASURE)	Percentage of patients who were prescribed potent antiretroviral therapy
0407	162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	HIV RNA Control After Six months of Potent Antiretroviral Therapy	Percentage of patients with viral load below limits of quantification OR patients with viral load not below limits of quantification who have a documented plan of care

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
0056	163	Diabetes Mellitus: Foot Exam	Coronary Artery Bypass Graft (CABG): Diabetes: Foot exam	Percentage of adult patients with diabetes aged 18–75 years who received a foot exam (visual inspection, sensory exam with monofilament, or pulse exam)
0129	164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation)	Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation)	Percent of patients undergoing isolated CABG (without pre-existing intubation/tracheostomy) who require intubation for more than 24 hours
0130	165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	Percent of patients undergoing isolated CABG who developed deep sternal wound infection within 30 days post-operatively
0131	166	Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident (CVA)	Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident	Percent of patients undergoing isolated CABG (without pre-existing neurologic deficit) who develop a post-operative neurologic deficit persisting greater than 72 hours
0114	167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Insufficiency	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure	Percent of patients undergoing isolated CABG (without pre-existing renal failure) who develop post-operative renal failure or require dialysis
0115	168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	Percent of patients undergoing isolated CABG who require a return to the operating room for bleeding/tamponade, graft occlusion, or other cardiac reason
0116	169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	Coronary Artery Bypass Graft (CABG): Anti-Platelet Medication at Discharge	Percent of patients undergoing isolated CABG who were discharged on aspirin/safety-coated aspirin or clopidogrel
0117	170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	Coronary Artery Bypass Graft (CABG): Beta Blockade at Discharge	Percent of patients undergoing isolated CABG who were discharged on beta blockers
0118	171	Coronary Artery Bypass Graft (CABG): Lipid Management and Counseling	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment Discharge	Percent of patients undergoing isolated CABG who were discharged on a statin or other pharmacologic lipid-lowering regimen
0259	172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous	Hemodialysis Vascular Access— Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous	Percentage of patients with advanced chronic disease (CKD4 or 5) or end-stage renal disease (ESRD) undergoing open surgical

NQF #	PQRS #	CMS Measure Name	NQF Measure Name	NQF Measure Description
		(AV) Fistula	Fistula	implantation of permanent hemodialysis access who receive an autogenous arterial venous fistula (AVF)
0399	183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	Paired Measure: Hepatitis C—Hepatitis A Vaccination (paired with 0400)	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who have received hepatitis A vaccination, or who have documented immunity
0400	184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	Paired Measure: Hepatitis C—Hepatitis B Vaccination (paired with 0399)	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who have received hepatitis B vaccination, or who have documented immunity
0659	185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	Endoscopy/Poly Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use	Percentage of patients aged 18 years and older receiving a surveillance colonoscopy, with a history of a prior colonic polyp in previous colonoscopy findings who had a follow-up interval of 3 or more years since their last colonoscopy documented in the colonoscopy report

Nursing Home Measure Name MDS 2.0 to MDS 3.0 Crosswalk

Long-Stay Residents (Chronic Care)

MDS 2.0 NQF#	Measure Name MDS 2.0	MDS 3.0 NQF#	Measure Name MDS 3.0
0432	Influenza Vaccination of Nursing Home / Skilled Nursing Facility Residents	0681	Percent of Long Stay Residents Assessed and Given, Appropriately, the Seasonal Influenza Vaccine
0433	Pneumococcal Vaccination of Nursing Home / Skilled Nursing Facility Residents	0683	Percent of Long Stay Residents Assessed and Given, Appropriately, the Seasonal Influenza Vaccine
0182	Residents Whose Need for More Help with Daily Activities Has Increased	0688	Percent of Residents Whose Need for Help with Daily Activities Has Increased
0192	Residents Who Experience Moderate to Severe Pain During the 7-Day Assessment Period (risk-adjusted)	0677	Percent of Residents Who Self-Report Moderate to Severe Pain Changes were made from the MDS 2.0 measure
0198	High-Risk Residents with Pressure Ulcers	0679	Percent of High-Risk Residents with Pressure Ulcers Changes were made from the MDS 2.0 measure
0199	Average-Risk Residents with Pressure Ulcers		No MDS 3.0 equivalent measure

MDS 2.0 NQF#	Measure Name MDS 2.0	MDS 3.0 NQF#	Measure Name MDS 3.0
0193	Residents Who Were Physically Restrained Daily During the 7-Day Assessment Period	0687	Percent of Residents Who Were Physically Restrained
0197	Residents with Worsening of a Depressed or Anxious Mood	0690	Percent of Residents Who have Depressive Symptoms Changes were made from the MDS 2.0 measure
0183	Low-Risk Residents Who Frequently Lose Control of Their Bowel or Bladder	0685	Percent of Low-Risk Residents Who Lose Control of Their Bowels or Bladder
0184	Residents Who Have a Catheter in the Bladder at Any Time During the 14-Day Assessment Period. (risk adjusted)	0686	Residents Who Have/Had a Catheter Inserted and Left in Their Bladder
0194	Residents Who Spent Most of Their Time in Bed or in a Chair in Their Room During the 7-Day Assessment Period		No MDS 3.0 equivalent measure
0195	Residents with a Decline in Their Ability to Move About in Their Room and the Adjacent Corridor		No MDS 3.0 equivalent measure
0196	Residents with a Urinary Tract Infection	0684	Percent of Long-Stay Residents with a Urinary Tract Infection
0191	Residents Who Lose Too Much Weight	0689	Percent of Long-Stay Residents Who Lose Too Much Weight
	No MDS 2.0 equivalent measure	0674	Percent of Residents Experiencing One or More Falls with Major Injury

Short-Stay Residents (Post-Acute Care)

MDS 2.0 NQF#	Measure Name MDS 2.0	MDS 3.0 NQF#	Measure Name MDS 3.0
0432	Influenza Vaccination of Nursing Home / Skilled Nursing Facility Residents	0680	Percent of Residents Assessed and Given, Appropriately, the Seasonal Influenza Vaccine
0433	Pneumococcal Vaccination of Nursing Home / Skilled Nursing Facility Residents	0682	Percent of Residents Assessed and Given, Appropriately, the Pneumococcal Vaccine
0185	Recently Hospitalized Residents with Symptoms of Delirium (risk-adjusted)		No MDS 3.0 equivalent measure
	No MDS 2.0 equivalent measure	0675	The Percentage of Residents on a Scheduled Pain Medication Regimen on Admission Who Report a Decrease in Pain Intensity or Frequency
0186	Recently Hospitalized Residents Who Experienced Moderate to Severe Pain at Any Time During the 7-Day Assessment Period	0676	Percent of Residents Who Self-Report Moderate to Severe Pain Changes were made from the MDS 2.0 measure
0187	Recently Hospitalized Residents with Pressure Ulcers (risk adjusted)	0678	Percent of Residents with Pressure Ulcers That Are New or Worsened Changes were made from the MDS 2.0 measure

Home Health Measure Name Crosswalk

Healthcare Utilization Measure

NQF#	HHC Measure Name	NQF Measure Name
0171	Patients Who Had to Be Admitted to the Hospital.	Acute Care Hospitalization
0172	Patients Who Are Able to Live in the Community at Discharge	Discharged to Community
0173	Patients Receiving Home Health Care Who Need Urgent, Unplanned Medical Care	Any Emergent Care

Clinical Status Improvement Measures

NQF#	HHC Measure Name	NQF Measure Name
0167	Patients Who Get Better at Walking or Moving Around	Improvement in Ambulation/Locomotion
0174	Patients Who Get Better at Bathing	Improvement in Bathing
0176	Patients Who Get Better at Taking Their Drugs Correctly by Mouth	Improvement in Management of Oral Medications
0175	Patients Who Get Better at Getting In and Out of Bed	Improvement in Transferring ¹

Functional Status Improvement Measures

NQF#	HHC Measure Name	NQF Measure Name
0177	Patients Who Have Less Pain When Moving Around	Improvement in Pain Interfering With Activity
0179	Patients Whose Breathing Improved	Improvement in Dyspnea

Home Health OASIS-C: Based Publicly Reported Process Measures

NQF#	HHC Measure Name	Measure Name as Submitted to NQF
0526	How Often the Home Health Team Began Their Patients' Care in a Timely Manner.	Timely Initiation of Care
0522	How Often the Home Health Team Determined Whether Patients Received a Flu Shot For the Current Flu Season.	Influenza Immunization Received for Current Flu Season
0525	How Often the Home Health Team Determined Whether Their Patients Received a Pneumococcal Vaccine (Pneumonia Shot).	Pneumococcal Polysaccharide Vaccine Ever Received
0521	How Often the Home Health Team Treated Heart Failure (Weakening of the Heart) Patients' Symptoms.	Heart Failure Symptoms During Short-Term Episodes
0519	For Patients With Diabetes, How Often the Home Health Team Got Doctor's Orders, Gave Foot Care, and Taught Patients About Foot Care.	Diabetic Foot Care and Patient Education Implemented During Short-Term Episodes of Care

¹ The NQF measure name for this was changed to *Improvement in Bed Transferring* after its transition from OASIS-B1 to OASIS-C in 2010.

NQF#	HHC Measure Name	Measure Name as Submitted to NQF
0523	How Often the Home Health Team Checked Patients for Pain.	Pain Assessment Conducted
Not NQF-Endorsed	How Often the Home Health Team Treated Their Patients' Pain.	Pain Interventions Implemented During Short-Term Episodes
0518	How Often the Home Health Team Checked Patients for Depression.	Depression Assessment Conducted
Not NQF-Endorsed	How Often the Home Health Team Taught Patients (Or Their Family Caregivers) About Their Drugs.	Drug Education on All Medications Provided to Patient/Caregiver During Short-Term Episodes
0537	How Often the Home Health Team Checked Patients' Risk of Falling.	Multifactor Fall-Risk Assessment Conducted for Patients 65 and Over
0540	How Often the Home Health Team Checked Patients for the Risk of Developing Pressure Sores (Bed Sores).	Pressure Ulcer Risk Conducted
0538	How Often the Home Health Team Included Treatments to Prevent Pressure Sores (Bed Sores) In the Plan of Care	Pressure Ulcer Prevention Included in the Plan of Care
Not NQF-Endorsed	How Often the Home Health Team Took Doctor-Ordered Action to Prevent Pressure Sores (Bed Sores).	Pressure Ulcer Prevention Implemented During Short-Term Episodes of Care

Home Health OASIS-C Item Changes

OASIS-B1 Item	Measure	OASIS-C Item	Measure
M0420	Frequency of Pain Interfering with Patient's Activity or Movement: 0 - Patient has no pain or pain does not interfere with activity or movement 1 - Less often than daily 2 - Daily, but not constantly 3 - All of the time	M1242	Frequency of Pain Interfering with Patient's Activity or Movement: 0 - Patient has no pain 1 - Patient has pain that does not interfere with activity or movement 2 - Less often than daily 3 - Daily, but not constantly 4 - All of the time
M0670	Bathing: Ability to wash entire body, excludes grooming (washing face and hands only). Prior 0 - Able to bathe self in shower or tub independently. 1 - With the use of devices, is able to bathe self in shower or tub independently. 2 - Able to bathe in shower or tub with the assistance of another person: (a) for intermittent supervision or encouragement or reminders, OR (b) to get in and out of the shower or tub, OR (c) for washing difficult to reach areas. 3 - Participates in bathing self in shower or tub, but requires presence of another person	M1830	Bathing: Current ability to wash entire body safely, excludes grooming (washing face, washing hands and shampooing hair) Prior (status no longer collected) Current 0 - Able to bathe self in shower or tub independently, including getting in and out of tub/shower. 1 - With the use of devices, is able to bathe self in shower or tub independently, including getting in and out of the tub/shower. 2 - Able to bathe in shower or tub with the intermittent assistance of another person: (a) for intermittent supervision or encouragement or reminders, OR (b) to get in and out of the shower

OASIS-B1 Item	Measure	OASIS-C Item	Measure
	<p>throughout the bath for assistance or supervision.</p> <p>4 - Unable to use the shower or tub and is bathed in bed or bedside chair.</p> <p>5 - Unable to effectively participate in bathing and is totally bathed by another person.</p> <p>UK - Unknown</p> <p>Current</p> <p>0 - Able to bathe self in shower or tub independently.</p> <p>1 - With the use of devices, is able to bathe self in shower or tub independently.</p> <p>2 - Able to bathe in shower or tub with the assistance of another person: (a) for intermittent supervision or encouragement or reminders, OR (b) to get in and out of the shower or tub, OR (c) for washing difficult to reach areas.</p> <p>3 - Participates in bathing self in shower or tub, but requires presence of another person throughout the bath for assistance or supervision.</p> <p>4 - Unable to use the shower or tub and is bathed in bed or bedside chair.</p> <p>5 - Unable to effectively participate in bathing and is totally bathed by another person.</p>		<p>or tub, OR (c) for washing difficult to reach areas.</p> <p>3 - Able to participate in bathing self in shower or tub, but requires presence of another person throughout the bath for assistance or supervision.</p> <p>4 - Unable to use the shower or tub, but able to bathe self independently, with or without the use of devices, at the sink, in chair, or on commode.</p> <p>5 - Unable to use the shower or tub, but able to participate in bathing self in bed, at the sink, in bedside chair, or on commode, with the assistance or supervision of another person throughout the bath.</p> <p>6 - Unable to participate effectively in bathing and is bathed totally by another person.</p>
M0690	<p>Transferring: Ability to move from bed to chair, on and off toilet or commode, into and out of tub or shower, and ability to turn and position self in bed if patient is bedfast.</p> <p>Prior</p> <p>0 - Able to independently transfer.</p> <p>1 - Transfers with minimal human assistance or with use of an assistive device.</p> <p>2 - Unable to transfer self but is able to bear weight and pivot during the transfer process.</p> <p>3 - Unable to transfer self and is unable to bear weight or pivot when transferred by another person.</p> <p>4 - Bedfast, unable to transfer but is able to turn and position self in bed.</p> <p>5 - Bedfast, unable to transfer and is unable to turn and position self.</p> <p>UK - Unknown</p> <p>Current</p> <p>0 - Able to independently transfer.</p> <p>1 - Transfers with minimal human assistance or with use of an assistive device.</p>	M1850	<p>Transferring: Current ability to move safely from bed to chair, or ability to turn and position self in bed if patient is bedfast.</p> <p>Prior (status no longer collected)</p> <p>Current</p> <p>0 - Able to independently transfer.</p> <p>1 - Able to transfer with minimal human assistance or with use of an assistive device.</p> <p>2 - Able to bear weight and pivot during the transfer process but unable to transfer self.</p> <p>3 - Unable to transfer self and is unable to bear weight or pivot when transferred by another person.</p> <p>4 - Bedfast, unable to transfer but is able to turn and position self in bed.</p> <p>5 - Bedfast, unable to transfer and is unable to turn and position self</p>

OASIS-B1 Item	Measure	OASIS-C Item	Measure
	<p>2 - Unable to transfer self but is able to bear weight and pivot during the transfer process.</p> <p>3 - Unable to transfer self and is unable to bear weight or pivot when transferred by another person.</p> <p>4 - Bedfast, unable to transfer but is able to turn and position self in bed.</p> <p>5 - Bedfast, unable to transfer and is unable to turn and position self.</p>		
M0700	<p>Ambulation/Locomotion: Ability to SAFELY walk, once in a standing position, or use a wheelchair, once in a seated position, on a variety of surfaces.</p> <p>Prior</p> <p>0 - Able to independently walk on even and uneven surfaces and climb stairs with or without railings (i.e., needs no human assistance or assistive device).</p> <p>1 - Requires use of a device (e.g., cane, walker) to walk alone or requires human supervision or assistance to negotiate stairs or steps or uneven surfaces.</p> <p>2 - Able to walk only with the supervision or assistance of another person at all times.</p> <p>3 - Chairfast, unable to ambulate but is able to wheel self independently.</p> <p>4 - Chairfast, unable to ambulate and is unable to wheel self.</p> <p>5 - Bedfast, unable to ambulate or be up in a chair.</p> <p>UK – Unknown</p> <p>Current</p> <p>0 - Able to independently walk on even and uneven surfaces and climb stairs with or without railings (i.e., needs no human assistance or assistive device).</p> <p>1 - Requires use of a device (e.g., cane, walker) to walk alone or requires human supervision or assistance to negotiate stairs or steps or uneven surfaces.</p> <p>2 - Able to walk only with the supervision or assistance of another person at all times.</p> <p>3 - Chairfast, unable to ambulate but is able to wheel self independently.</p> <p>4 - Chairfast, unable to ambulate and is unable to wheel self.</p> <p>5 - Bedfast, unable to ambulate or be up in a chair.</p>	M1860	<p>Ambulation/Locomotion: Current ability to walk safely, once in a standing position, or use a wheelchair, once in a seated position, on a variety of surfaces.</p> <p>Prior (status no longer collected)</p> <p>Current</p> <p>0 -Able to independently walk on even and uneven surfaces and negotiate stairs with or without railings (i.e., needs no human assistance or assistive device).</p> <p>1 - With the use of a one-handed device (e.g. cane, single crutch, hemi-walker), able to independently walk on even and uneven surfaces and negotiate stairs with or without railings.</p> <p>2 - Requires use of a two-handed device (e.g., walker or crutches) to walk alone on a level surface and/or requires human supervision or assistance to negotiate stairs or steps or uneven surfaces.</p> <p>3 - Able to walk only with the supervision or assistance of another person at all times.</p> <p>4 - Chairfast, unable to ambulate but is able to wheel self independently.</p> <p>5 - Chairfast, unable to ambulate and is unable to wheel self.</p> <p>6 - Bedfast, unable to ambulate or be up in a chair</p>

OASIS-B1 Item	Measure	OASIS-C Item	Measure
M0780	<p>Management of Oral Medications: Patient's ability to prepare and take all prescribed oral medications reliably and safely, including administration of the correct dosage at the appropriate times/intervals. Excludes injectable and IV medications. (NOTE: This refers to ability, not compliance or willingness.)</p> <p>Prior 0 - Able to independently take the correct oral medication(s) and proper dosage(s) at the correct times. 1 - Able to take medication(s) at the correct times if: (a) individual dosages are prepared in advance by another person; OR (b) given daily reminders; OR (c) someone develops a drug diary or chart. 2 - Unable to take medication unless administered by someone else. NA - No oral medications prescribed. UK – Unknown</p> <p>Current 0 - Able to independently take the correct oral medication(s) and proper dosage(s) at the correct times. 1 - Able to take medication(s) at the correct times if: (a) individual dosages are prepared in advance by another person; OR (b) given daily reminders; OR (c) someone develops a drug diary or chart. 2 - Unable to take medication unless administered by someone else. NA - No oral medications prescribed.</p>	M2020	<p>Management of Oral Medications: Patient's current ability to prepare and take all oral medications reliably and safely, including administration of the correct dosage at the appropriate times/intervals. Excludes injectable and IV medications. (NOTE: This refers to ability, not compliance or willingness.)</p> <p>Prior (status no longer collected) Current 0 - Able to independently take the correct oral medication(s) and proper dosage(s) at the correct times. 1 - Able to take medication(s) at the correct times if: (a) individual dosages are prepared in advance by another person; OR (b) another person develops a drug diary or chart. 2 - Able to take medication(s) at the correct times if given reminders by another person at the appropriate times 3 - Unable to take medication unless administered by another person. NA - No oral medications prescribed.</p>

End Stage Renal Disease Measure Name Crosswalk

NQF #	CMS Web Site Measure Name	NQF Measure Name
0369	Patient Survival Rates: Actual Compared to Expected	Dialysis Facility Risk-Adjusted Standardized Mortality Ratio Level

Medicare Part C Measure Name Crosswalk

Staying Healthy: Screenings, Tests, and Vaccines

NQF #	CMS Web Site Measure Name	NQF Measure Name
0031	Breast Cancer Screening	Breast Cancer Screening
0034	Colorectal Cancer Screening	Colorectal Cancer Screening
0075	Cholesterol Screening for Patients with Heart Disease	IVD: Complete Lipid Profile and LDL Control < 100

NQF #	CMS Web Site Measure Name	NQF Measure Name
0064	Cholesterol Screening for Patients with Diabetes	Diabetes Measure Pair: A Lipid Management: Low Density Lipoprotein Lipid Management: LDL-C < 100.
0040	Annual Flu Vaccine	Flu Shot for Older Adults (CAHPS)
0043	Pneumonia Vaccine	Pneumonia Vaccination Status for Older Adults (CAHPS).
0029	Monitoring Physical Activity	Counseling on Physical Activity in Older Adults <ul style="list-style-type: none"> • Discussing Physical Activity • Advising Physical Activity (HOS).

Managing Chronic (Long-Term) Conditions

NQF #	CMS Web Site Measure Name	NQF Measure Name
0553	Yearly Review of All Medications and Supplements Being Taken (collected by SNP only)	Care for Older Adults – Medication Review
0053	Osteoporosis Management	Osteoporosis Management in Women Who Had a Fracture
0055	Eye Exam to Check for Damage from Diabetes	Diabetes: Eye Exam
0062	Kidney Function Testing for Members with Diabetes	Diabetes: Urine Protein Screening
0059	Plan Members with Diabetes Whose Blood Sugar Is Under Control	Hemoglobin A1c Management
0064	Plan Members with Diabetes Whose Cholesterol Is Under Control	Diabetes Measure Pair: A Lipid Management: Low Density Lipoprotein Lipid Management: LDL-C <100
0018	Controlling Blood Pressure	Controlling High Blood Pressure
0054	Rheumatoid Arthritis Management	Arthritis: Disease Modifying Antirheumatic Drug (DMARD) Therapy in Rheumatoid Arthritis
0030	Improving Bladder Control	Urinary Incontinence Management in Older Adults – <ul style="list-style-type: none"> • Discussing Urinary Incontinence • Receiving Urinary Incontinence Treatment (HOS)
0035	Reducing the Risk of Falling	Fall-Risk Management in Older Adults: (a) Discussing Fall Risk, (b) Managing Fall Risk (HOS)

Ratings of Plan Responsiveness and Care

NQF #	CMS Web Site Measure Name	NQF Measure Name
0006	Ease of Getting Needed Care and Seeing Specialists	CAHPS Health Plan Survey v 4.0 – Adult Questionnaire
0006	Getting Appointments and Care Quickly	CAHPS Health Plan Survey v 4.0 – Adult Questionnaire
0006	Customer Service	CAHPS Health Plan Survey v 4.0 – Adult Questionnaire
0006	Overall Rating of Health Care Quality	CAHPS Health Plan Survey v 4.0 – Adult Questionnaire
0006	Members' Overall Rating of Health Plan	CAHPS Health Plan Survey v 4.0 – Adult Questionnaire

Medicare Part D Measure Name Crosswalk

NQF#	CMS Web Site Measure Name	NQF Measure Name
0022	Drug Plan Members 65 and Older Who Receive Prescriptions for Certain Drugs with a High Risk of Side Effects, When There May Be Safer Drug Choices	Drugs to Be Avoided in the Elderly: (a) Patients Who Receive at Least One Drug to Be Avoided, and (b) Patients Who Receive at Least Two Different Drugs to Be Avoided
0546	Using the Kind of Blood Pressure Medication That Is Recommended for People with Diabetes	Diabetes Suboptimal Treatment Regimen (SUB)